Due to its Von Hippel-Lindau E3 ligase it is thought to not relevantly degrade Bcl-XL in platelets, which might lead to less thrombocytopenia when compared to previous Bcl-XL inhibitors like ABT263 and might therefore be more tolerable [102]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.